Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Lung cancer symbols : Azn save search
Non-small Cell Lung Cancer Drugs Market to Grow by USD 30.23 billion| Increasing Prevalence and Incidence of Non-small Cell Lung Cancer to Boost Market Growth | Technavio
Published: 2022-03-08 (Crawled : 08:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -2.09%
H: 5.03%
C: 0.85%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 1.01%
H: 0.81%
C: -0.06%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.29%
H: 0.6%
C: -1.24%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
drug cel lung cancer cancer drug cancer growth
HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer
Published: 2022-03-07 (Crawled : 05:00) - globenewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: -1.8%
HCM | $16.38 -0.43% -0.43% 190K
|
Health Technology
|
| O: -10.68%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -1.33%
H: 0.0%
C: 0.0%
orpathys star lung cancer one cancer milestone
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2022-03-02 (Crawled : 14:00) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 0.37%
H: 2.02%
C: 2.02%
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 3.95%
H: 5.06%
C: -7.17%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
tagrisso gene therapy trial cel lung cancer phase 1 therapy cancer
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 2.49%
H: 1.06%
C: -2.49%
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 16.79%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: 0.07%
keytruda fast track designation treatment fda fast track gene therapy cel fda fast track lung cancer therapy cancer designation
DESTINY-Lung04 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2021-12-23 (Crawled : 14:00) - biospace.com/
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -1.0%
H: 0.71%
C: 0.24%
enhertu trial cel lung cancer cancer phase 3 initiated her2- her2
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
Published: 2021-11-24 (Crawled : 01:00) - globenewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -0.02%
H: 1.33%
C: 1.33%
HCM | $16.38 -0.43% -0.43% 190K
|
Health Technology
|
| O: -4.39%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
orpathys lung cancer china therapy cancer trial
Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.11%
H: 0.03%
C: -0.27%
lung cancer collaboration cancer trial initiated keytruda
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
Published: 2021-09-08 (Crawled : 11:00) - globenewswire.com
HCM | $16.38 -0.43% -0.43% 190K
|
Health Technology
|
| O: -2.29%
H: 1.34%
C: 1.29%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -1.85%
H: 0.17%
C: -0.42%
lung cancer china therapy cancer trial
HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations
Published: 2021-06-22 (Crawled : 18:00) - globenewswire.com
HCM | $16.38 -0.43% -0.43% 190K
|
Health Technology
|
| O: 3.66%
H: 1.31%
C: -4.82%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.26%
H: 0.28%
C: -0.46%
lung cancer china cancer
Press news Biocartis Group NV: Biocartis Announces New Collaboration with AstraZeneca to Expand Availability of Idylla™ EGFR Biomarker Testing Among Patients with Lung Cancer
Published: 2021-05-04 (Crawled : 06:00) - globenewswire.com
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.8%
H: 0.21%
C: -0.64%
lung cancer test collaboration cancer biomarkers
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.